EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging

Chun-Han Huang, Palwasha Khan, Sulan Xu, Jules Cohen, Georgios V Georgakis, Nashaat Turkman iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25136870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Chun-Han Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Stony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Positron-Emission Tomography, Brain Neoplasms, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stony Brook Cancer Center Translational Research in Breast Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The synthesis, biochemical evaluation and radiosynthesis of a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor and radioligand was performed. NT431, a newly synthesized 4-fluorobenzyl-abemaciclib, exhibited high potency to CDK4/6 and against four cancer cell lines with IC50 similar to that of the parent abemaciclib. We performed a two-step one-pot radiosynthesis to produce [18F]NT431 with good radiochemical yield (9.6 ± 3%, n = 3, decay uncorrected), high radiochemical purity (>95%), and high molar activity (>370 GBq/µmol (>10.0 Ci/µmol). In vitro autoradiography confirmed the specific binding of [18F]NT431 to CDK4/6 in brain tissues. Dynamic PET imaging supports that both [18F]NT431 and the parent abemaciclib crossed the BBB albeit with modest brain uptake. Therefore, we conclude that it is unlikely that NT431 or abemaciclib (FDA approved drug) can accumulate in the brain in sufficient concentrations to be potentially effective against breast cancer brain metastases or brain cancers. However, despite the modest BBB penetration, [18F]NT431 represents an important step towards the development and evaluation of a new generation of CDK4/6 inhibitors with superior BBB penetration for the treatment and visualization of CDK4/6 positive tumors in the CNS. Also, [18F]NT431 may have potential application in peripheral tumors such as breast cancer and other CDK4/6 positive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Positron-Emission TomographyBrain NeoplasmsCyclin-Dependent Kinase 6BenzimidazolesAminopyridinesProtein Kinase InhibitorsHumansCell Line, TumorAnimalsRadiopharmaceuticalsFluorine RadioisotopesBrainMiceFemale

Stichwörter der Autor:innen

BBBCDK4/6CNSPETabemaciclib

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6abemaciclibBenzimidazolesAminopyridinesProtein Kinase InhibitorsRadiopharmaceuticalsCDK4 protein, humanFluorine RadioisotopesCDK6 protein, human

Autor:innen und Institutionen

  • Stony Brook Cancer Center, Stony Brook, Long Island, NY 11794, USA.
  • Department of Radiology, School of Medicine, Stony Brook University, Long Island, NY 11794, USA.
  • Department of Biomedical Engineering, Stony Brook University, Long Island, NY 11794, USA.
  • Department of Medicine, School of Medicine, Stony Brook University, Long Island, NY 11794, USA.
  • Department of Surgery, School of Medicine, Stony Brook University, Long Island, NY 11794, USA.

ORCID-Profile: Nashaat Turkman

Förderung

  • Stony Brook Cancer Center Translational Research in Breast Cancer

Zitieren

APA

Huang, C. H., Khan, P., Xu, S., Cohen, J., Georgakis, G. V., & Turkman, N. (2024). Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25136870

Vancouver

Huang CH, Khan P, Xu S, Cohen J, Georgakis GV, Turkman N. Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25136870

BibTeX
@article{Huang2024,
  author = {Huang, Chun-Han and Khan, Palwasha and Xu, Sulan and Cohen, Jules and Georgakis, Georgios V and Turkman, Nashaat},
  title = {Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25136870}
}
Kostenlos starten →